Ruiz Briseno Andres sold $382K of IDYA

Ruiz Briseno Andres (Chief Accounting Officer) sold 9,550 shares of IDEAYA Biosciences, Inc. (IDYA) at $40.01 ($0.38M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ruiz Briseno Andres
Published Jul 9, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDYA
Neutral
high confidence
Mentioned
$IDYA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDYANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the CFO under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment monitoring, but there is no accompanying fundamental update.

03

What to watch

The disclosure does not indicate why the sale occurred, and 10b5-1 plans are often used to reduce timing-based inference.

Relevance 3/10Novelty 2/10Timing: Filed on 2026-07-09, covering a sale executed on 2026-07-07.

Background

The article is an SEC Form 4 insider transaction for IDEAYA Biosciences, Inc.

Company-level read

Ticker impact

$IDYANeutralHigh confidence
Context

IDEAYA Biosciences CFO Ruiz Briseno Andres sold 9,550 shares for about $382.1K under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more about signaling than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and it provides no new company performance, guidance, or regulatory/clinical event.

Market effects

No clear read-across to biotech sector fundamentals from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Insider selling can still be interpreted as caution, even if 10b5-1, especially if repeated frequently.

Key entities

  • IDEAYA Biosciences, Inc.

    Company whose CFO insider sale is disclosed on Form 4.

  • Ruiz Briseno Andres

    Chief Accounting Officer who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDYAMed

IDEAYA Biosciences Q3 loss widens to $125.7M

IDEAYA Biosciences reported a Q3 2026 net loss of $125.7M, up from $112.5M in Q2, with collaboration revenue rising to $10.2M. Cash reserves fell to $1.15B. The company submitted darovasertib for FDA approval and plans Phase 3 trials, maintaining its cash runway guidance into 2030.

$IDYAHighAI 8/10

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

IDEAYA Biosciences, Inc. (IDYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update • Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanom

$IDYAHighAI 9/10

IDEAYA Reports Promising IDE849 Results In Small Cell Lung Cancer

IDEAYA Biosciences reported Phase 1 results for IDE849, showing antitumor activity in relapsed small cell lung cancer. Median overall survival was 17.4 months in second-line SCLC and 14.7 months across second-line and later-line patients. The confirmed response rate was 60.8% in second-line SCLC. IDEAYA plans Phase 3 trials. The stock closed at $36.12, up 1.83%, and is down 0.03% in premarket trading.